Canopy(1) | $22,000,000 | (Jan 13, 2026)
Onsetto | $2,200,000 | (Jan 13, 2026)
BlueNalu | $11,000,000 | (Jan 13, 2026)
Validose
United States
- Brooklyn, NY
- 28/02/2025
- Pre-Seed
- $2,000,000
At Validose, we are redefining clinical drug adherence with smart-dose technology, real-time data insights, and personalized patient coaching—empowering clinical trials, accelerating pharmaceutical decision-making, and improving health outcomes.
Our Mission
To elevate health outcomes through precise, real-time adherence insights that drive personalized treatment approaches and transform how healthcare optimizes individual dosing and long-term efficacy.
How We Drive Success
Objective, Actionable Insights – Seamless integration of precise adherence data with an intuitive API for real-time decision-making.
Flexible, Scalable Platform – A modular, customizable hardware/software ecosystem designed for standalone or integrated use.
Comprehensive Behavior Approach – AI-driven personalized coaching and live interventions to enhance patient adherence.
Real-Time Data & Immediate Action – Instant connectivity enabling proactive engagement and accelerated clinical decisions.
We are creating a new standard in adherence—where insights drive action, decisions are streamlined, and outcomes are improved.
#HealthTech #ClinicalTrials #SmartDose #DigitalHealth
- Industry Medical Device
- Website https://validose.com/
- LinkedIn https://www.linkedin.com/company/validose/
Related People
Paul McGrathFounder
United States -
New York, New York
I am a health technology leader dedicated to enhancing health outcomes through innovative data and technology applications. As the CEO of Validose, I focus on addressing the critical issue of drug adherence in the U.S. by developing an intelligent technology dosing & data system that ensures safe and controlled medication use. My work is guided by the principles of agile health tech models, where we build science-driven, clinically relevant solutions that bridge gaps in health innovation. My expertise spans general management, P&L ownership, global brand leadership, and creating high-performing, data-driven teams.
Specialties:
Organizational / Enterprise Leadership
Digital Health Innovation & Health Technology Applications
Agile Health Tech Development
Data-Driven Marketing & Brand Building
Drug Adherence Solutions
Global Market Expansion & Strategic Partnerships
Fundraising
P&L Ownership & Business Planning
Building & Leading High-Performing Teams
Market Access & Commercialization Strategies
Digital Transformation & E-commerce Growth
Innovation & New Product Launches
Value Proposition & Pricing Strategies
Integrated Patient & HCP Strategy
Omnichannel Strategy & Execution
Managing Large & Smaller Brands
Compliance & Risk Management
Scientific Storytelling & Medical Affairs
Cytotheryx, Inc. | $60,000,000 | (Jan 13, 2026)
MEDIPOST, Inc. | $140,000,000 | (Jan 13, 2026)
TRYBE | $30,000,000 | (Jan 13, 2026)
Kinaset Therapeutics | $103,000,000 | (Jan 13, 2026)
Diagonal Therapeutics | $125,000,000 | (Jan 13, 2026)
VelaFi | $20,000,000 | (Jan 13, 2026)
encoord | $2,000,000 | (Jan 13, 2026)
Vibrant Therapeutics | $61,000,000 | (Jan 13, 2026)
Avenue Biosciences | $7,500,000 | (Jan 13, 2026)
Unusual | $3,600,000 | (Jan 13, 2026)